13 search results for: disease severity

ERS-ISIAN 2025 | Type 2 Inflammation: Links with Severe/Uncontrolled CRSwNP
Rhinology
ERS-ISIAN 2025 | Type 2 Inflammation: Links with Severe/Uncontrolled CRSwNP
expert video

Prof. Vibeke Backer provides an insightful presentation on the association of type 2 inflammation and the pathogenesis and management of severe and uncontrolled CRSwNP.

View more
ADVENT On Air | First-hand Experience: Expert Insights on the Management of Atopic Hand and Foot Dermatitis
Dermatology
ADVENT On Air | First-hand Experience: Expert Insights on the Management of Atopic Hand and Foot Dermatitis
Podcast

This podcast episode discusses best practices for the diagnosis of atopic dermatitis of the hands and feet, as well as current and emerging treatment options.

View more
ADVENT On Air | First-hand Experience: Practical Insights On the Diagnosis and Assessment of Atopic Dermatitis of the Hands and Feet
Dermatology
ADVENT On Air | First-hand Experience: Practical Insights On the Diagnosis and Assessment of Atopic Dermatitis of the Hands and Feet
Podcast

This podcast episode discusses best practices for the diagnosis of atopic dermatitis of the hands and feet

View more
Compounded Burden of Co-existing Type 2 Airway <b>Disease</b>s
Pulmonology
Compounded Burden of Co-existing Type 2 Airway Diseases
expert video

In this video soundbite from the EAACI 2025 symposium, Dr. Brian Lipworth discusses that co-existing type 2 inflammatory diseases are common in patients with CRSwNP​ & increasing severity of asthma is associated with higher severity of CRS and prevalence of nasal polyps. Additionally, he explains that patient burden is substantially greater when asthma and CRSwNP are co-existing.

View more
ERS-ISIAN 2025 | Type 2 Inflammation and <b>Disease</b> Control in CRSwNP: Current Perspectives and Future Directions
Rhinology
ERS-ISIAN 2025 | Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions
expert video

The ERS-ISIAN 2025 symposium, featuring Prof. Vibeke Backer and Prof. Sietze Reitsma, titled "Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions," will delve into the complexities of the role of type 2 inflammation in CRSwNP.

View more
ADVENT at ERS-ISIAN 2025
On Demand
ERS-ISIAN 2025 | Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions

In this educational presentation, Profs. Vibeke Backer and Sietze Reitsma cover key aspects of type 2 inflammation and its role in the pathogenesis and management of CRSwNP and practical strategies for optimizing disease control and improving patient outcomes.

What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?
Rhinology
What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?
expert video

Prof. Hellings and Prof. Corso highlight that disease severity plays a key role in rate and control of remission in CRS.

View more
The Burden in Patients with CRSwNP and Coexisting Asthma
Pulmonology
The Burden in Patients with CRSwNP and Coexisting Asthma
expert video

This video supports improved clinical awareness and encourages comprehensive care strategies for patients living with both CRSwNP and asthma.

View more
How does a decrease in smell affect sleep disturbance? Is there any direct relation?
Rhinology
How does a decrease in smell affect sleep disturbance? Is there any direct relation?
expert video

Prof. Mullol share his opinion on connection between loss of smell and sleep disorder in patients with CRSwNP.

View more
On the Surface: Restoring the Skin Barrier in Patients With AD
Dermatology
On the Surface: Restoring the Skin Barrier in Patients With AD
expert video

In this video from the April 2025 WCPD symposium, Dr Amy Paller discusses the pathophysiology of skin barrier dysfunction in AD and how regulating IL-4 and IL-13 signaling may lead to restoration of the skin barrier. Dr Paller goes on to explore how reducing certain biomarkers, such as CCL17 (TARC), may reduce inflammation that contributes to AD severity in pediatric patients.

View more